Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 3
2006 3
2007 7
2008 10
2009 7
2010 9
2011 3
2012 13
2013 8
2014 9
2015 7
2016 8
2017 7
2018 6
2019 14
2020 10
2021 8
2022 3
2023 1
2024 2
2025 13
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome.
Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, Pease CT, Price EJ, Sutcliffe N, Gendi NST, Hall FC, Ruddock SP, Fernandez C, Reynolds C, Hulme CT, Davies KA, Edwards CJ, Lanyon PC, Moots RJ, Roussou E, Giles IP, Sharples LD, Bombardieri M. Bowman SJ, et al. Arthritis Rheumatol. 2017 Jul;69(7):1440-1450. doi: 10.1002/art.40093. Epub 2017 Jun 5. Arthritis Rheumatol. 2017. PMID: 28296257 Free article. Clinical Trial.
OBJECTIVE: To investigate whether rituximab, an anti-B cell therapy, improves symptoms of fatigue and oral dryness in patients with primary Sjogren's syndrome (SS). ...Other outcome measures included salivary and lacrimal flow rates, quality of life, scores o …
OBJECTIVE: To investigate whether rituximab, an anti-B cell therapy, improves symptoms of fatigue and oral dryness in patients with p …
A randomized, phase II study of sequential belimumab and rituximab in primary Sjogren's syndrome.
Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, Lerang K, Mistry P, Punwaney R, Seror R, Stone J, van Daele P, van Maurik A, Wisniacki N, Roth DA, Tak PP. Mariette X, et al. JCI Insight. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030. JCI Insight. 2022. PMID: 36477362 Free PMC article. Clinical Trial.
BACKGROUNDPrimary Sjogren's syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). ...At week 68, mean ( standard error) total EULAR Sjogren's syndrome disease activity index scores decreased from 11.0 (1. …
BACKGROUNDPrimary Sjogren's syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS …
Membranous Nephropathy: Core Curriculum 2021.
Alsharhan L, Beck LH Jr. Alsharhan L, et al. Am J Kidney Dis. 2021 Mar;77(3):440-453. doi: 10.1053/j.ajkd.2020.10.009. Epub 2021 Jan 21. Am J Kidney Dis. 2021. PMID: 33487481 Review.
Although immunosuppression with alkylating agents combined with corticosteroids, or with calcineurin inhibitor-based regimens, has been the historical mainstay of treatment, observational and now randomized controlled trials with the B-cell-depleting agent rituximab …
Although immunosuppression with alkylating agents combined with corticosteroids, or with calcineurin inhibitor-based regimens, has been the …
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.
Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O. Kaegi C, et al. Front Immunol. 2019 Sep 6;10:1990. doi: 10.3389/fimmu.2019.01990. eCollection 2019. Front Immunol. 2019. PMID: 31555262 Free PMC article.
This systematic review is the first of a series of articles assessing the safety and efficacy of B cell-targeting biologics for the treatment of immune-mediated diseases. Objective: To evaluate rituximab's safety and efficacy for the treatment of immune-mediated dis …
This systematic review is the first of a series of articles assessing the safety and efficacy of B cell-targeting biologics for the treatmen …
Novel therapies in Sjogren's disease: A systematic review of the literature.
Pelkas C, Franke KB, Vincent FB, Rischmueller M. Pelkas C, et al. Best Pract Res Clin Rheumatol. 2025 Dec;39(4):102084. doi: 10.1016/j.berh.2025.102084. Epub 2025 Jul 7. Best Pract Res Clin Rheumatol. 2025. PMID: 40628622 Free article.
Sjogren's disease (SjD) is a chronic systemic autoimmune disorder that primarily involves lymphocytic infiltration of exocrine glands, with frequent extra-glandular manifestations. Historically, treatment options for SjD have been limited to alleviating symptoms, ra …
Sjogren's disease (SjD) is a chronic systemic autoimmune disorder that primarily involves lymphocytic infiltration of exocrine …
Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjogren Syndrome (CRESS) and Sjogren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjogren Syndrome (TRACTISS).
Pontarini E, Sciacca E, Chowdhury F, Grigoriadou S, Rivellese F, Murray-Brown WJ, Lucchesi D, Fossati-Jimack L, Nerviani A, Jaworska E, Ghirardi GM, Giacomassi C, Emery P, Ng WF, Sutcliffe N, Everett C, Fernandez C, Tappuni A, Seror R, Mariette X, Porcher R, Cavallaro G, Pulvirenti A, Verstappen GM, de Wolff L, Arends S, Bootsma H, Lewis MJ, Pitzalis C, Bowman SJ, Bombardieri M; Trial for Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome Study Research Group. Pontarini E, et al. Arthritis Rheumatol. 2024 May;76(5):763-776. doi: 10.1002/art.42772. Epub 2024 Feb 15. Arthritis Rheumatol. 2024. PMID: 38073013 Clinical Trial.
OBJECTIVE: This study aimed to identify peripheral and salivary gland (SG) biomarkers of response/resistance to B cell depletion based on the novel concise Composite of Relevant Endpoints for Sjogren Syndrome (cCRESS) and candidate Sjogren Tool for Assessing Respons …
OBJECTIVE: This study aimed to identify peripheral and salivary gland (SG) biomarkers of response/resistance to B cell depletion based on th …
Development and preliminary validation of the Sjogren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjogren's syndrome.
Seror R, Baron G, Camus M, Cornec D, Perrodeau E, Bowman SJ, Bombardieri M, Bootsma H, Gottenberg JE, Fisher B, Hueber W, van Roon JA, Devauchelle-Pensec V, Gergely P, Mariette X, Porcher R; NECESSITY WP5 - STAR development working group; NECESSITY WP5- STAR development working group. Seror R, et al. Ann Rheum Dis. 2022 Jul;81(7):979-989. doi: 10.1136/annrheumdis-2021-222054. Epub 2022 Apr 7. Ann Rheum Dis. 2022. PMID: 35393271 Free PMC article.
OBJECTIVE: To develop a composite responder index in primary Sjogren's syndrome (pSS): the Sjogren's Tool for Assessing Response (STAR). METHODS: To develop STAR, the NECESSITY (New clinical endpoints in primary Sjogren's syndrome: …
OBJECTIVE: To develop a composite responder index in primary Sjogren's syndrome (pSS): the Sjogren's Tool for As …
Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjogren's syndrome: evidence- and practice-based guidance.
Marinho A, Delgado Alves J, Fortuna J, Faria R, Almeida I, Alves G, Araújo Correia J, Campar A, Brandão M, Crespo J, Marado D, Matos-Costa J, Oliveira S, Salvador F, Santos L, Silva F, Fernandes M, Vasconcelos C. Marinho A, et al. Front Immunol. 2023 Apr 17;14:1117699. doi: 10.3389/fimmu.2023.1117699. eCollection 2023. Front Immunol. 2023. PMID: 37138867 Free PMC article. Review.
Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjogren's syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and refractory/intolerance to conventional immunosuppressants demand other options, namely biological drugs, …
Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjogren's syndrome (SS) are heterogeneous autoimmune …
Rituximab Therapy for Primary Sjogren's Syndrome.
Chen YH, Wang XY, Jin X, Yang Z, Xu J. Chen YH, et al. Front Pharmacol. 2021 Sep 2;12:731122. doi: 10.3389/fphar.2021.731122. eCollection 2021. Front Pharmacol. 2021. PMID: 34539411 Free PMC article. Review.
Primary Sjogren's syndrome (pSS) is a systemic autoimmune diseases of the connective tissues, characteristic of the presentation of keratoconjunctivitis sicca and xerostomia. ...Nonetheless, the data available from clinical trials with RTX are often co …
Primary Sjogren's syndrome (pSS) is a systemic autoimmune diseases of the connective tissues, characteristic of the presentati …
Treatment of primary Sjogren syndrome with rituximab: a randomized trial.
Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Pers JO, Nowak E, Saraux A. Devauchelle-Pensec V, et al. Ann Intern Med. 2014 Feb 18;160(4):233-42. doi: 10.7326/M13-1085. Ann Intern Med. 2014. PMID: 24727841 Clinical Trial.
OBJECTIVE: To evaluate efficacy and harms of rituximab in adults with recent-onset or systemic pSS. DESIGN: Randomized, placebo-controlled, parallel-group trial conducted between March 2008 and January 2011. ...The proportion of patients with at least 30-mm decrease …
OBJECTIVE: To evaluate efficacy and harms of rituximab in adults with recent-onset or systemic pSS. DESIGN: Randomized, placebo-contr …
139 results